Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Integra Lifesciences Holdings (IART) Liabilities from Discontinued Operations (2020 - 2022)

Integra Lifesciences Holdings' Liabilities from Discontinued Operations history spans 3 years, with the latest figure at 2303000.0 for Q2 2022.

On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 2303000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was 2303000.0, a N/A change, with the full-year FY2020 number at 11751000.0, changed N/A from a year prior.
Liabilities from Discontinued Operations hit 2303000.0 in Q2 2022 for Integra Lifesciences Holdings, down from 11751000.0 in the prior quarter.
Over the last five years, Liabilities from Discontinued Operations for IART hit a ceiling of 12349000.0 in Q3 2020 and a floor of 2303000.0 in Q2 2022.